Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 7/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 16/20 | 0.47 |
| ▸ | FGFR2 | P21802 | 8/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.45 |
| ▸ | LYN | P07948 | 1/20 | 0.45 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.45 |
| ▸ | FLT4 | P35916 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | BLK | P51451 | 1/20 | 0.45 |
| ▸ | BMX | P51813 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.45 |
| ▸ | TAOK2 | Q9UL54 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19499677 | 0.87 | FGFR1 (0.46) | FGFR4FGFR1FGFR2CSF1RLYN | |
| SCHEMBL15412605 | 0.86 | FGFR1 (0.58) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL16668633 | 0.86 | FGFR4 (0.56) | FGFR4FGFR1FGFR2CSF1RLYN | |
| SCHEMBL28653536 | 0.84 | FGFR4 (0.56) | FGFR4FGFR1FGFR2CSF1RLYN | |
| SCHEMBL24335300 | 0.84 | FGFR1 (0.62) | FGFR4FGFR1FGFR2 | |
| SCHEMBL20434260 | 0.83 | FGFR1 (0.61) | FGFR4FGFR1FGFR2CSF1RLYN | |
| SCHEMBL17925412 | 0.83 | FGFR1 (0.41) | FGFR4FGFR1FGFR2CSF1RLYN | |
| SCHEMBL19499681 | 0.82 | FGFR4 (0.53) | FGFR4FGFR1FGFR2CSF1RLYN | |
| SCHEMBL20436170 | 0.82 | FGFR1 (0.60) | FGFR4FGFR1FGFR2CSF1RLYN | |
| SCHEMBL19507361 | 0.82 | FGFR1 (0.43) | FGFR1FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305918-A1 | DUAL-WARHEAD COVALENT INHIBITORS OF FGFR-4 | NEWAVE PHARMACEUTICAL INC. | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305918-A1 | DUAL-WARHEAD COVALENT INHIBITORS OF FGFR-4 | FGFR4, FGFR2, FGFR3 | FGFR4 1/4885FGFR1 4/4885FGFR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.